Skip to main content

Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia

  • Book
  • © 2016

Overview

  • Is a comprehensive, high-level clinical reference on the pathogenesis and therapy of hematological malignancies
  • Provides the clinical experience of TKIs such as imatinib, nilotinib, dasatinib, and ponatinib
  • Offers practical guidance on the therapeutic implications for understanding and managing CML

This is a preview of subscription content, log in via an institution to check access.

Access this book

eBook USD 16.99 USD 84.99
Discount applied Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 159.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (12 chapters)

Keywords

About this book

Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia provides a comprehensive understanding of the recent molecular genetics of Chronic Myelogenous Leukemia (CML) and a characterization of the molecular targets for drug development. Included are therapeutic implications, diagnosis, and prognosis for understanding and facilitating daily practice in the management of patients with CML.

Understanding of the pathogenesis and therapy of hematological malignancies such as CML has grown significantly in recent years. This development owe much to the progress in molecular biology and now makes a major contribution to diagnosis and to treatment that pharmacologically targets the molecular events of CML. Molecular targeting therapy with newly developed agents such as small molecules and antibodies for hematological malignancies are being discovered after years of research. Some of these, including tyrosine kinase inhibitors such as imatinib, nilotinib, and dasatinib, lead to increased survival rates and improved therapies. With the opinion leaders of basic and clinical research in the field as authors, this book reviews recent advances in the biology of CML.



Editors and Affiliations

  • Department of Hematology, Saitama Medical Center Saitama MEdical University, Kawagoe, Japan

    Masahiro Kizaki

About the editor

Professor and Chairman of Department of Hematology in Saitama Medical Center, Saitama Medical University.

Bibliographic Information

  • Book Title: Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia

  • Editors: Masahiro Kizaki

  • DOI: https://doi.org/10.1007/978-4-431-55714-2

  • Publisher: Springer Tokyo

  • eBook Packages: Medicine, Medicine (R0)

  • Copyright Information: Springer Japan 2016

  • Hardcover ISBN: 978-4-431-55713-5Published: 13 November 2015

  • Softcover ISBN: 978-4-431-56255-9Published: 23 August 2016

  • eBook ISBN: 978-4-431-55714-2Published: 05 November 2015

  • Edition Number: 1

  • Number of Pages: VIII, 193

  • Number of Illustrations: 6 b/w illustrations, 20 illustrations in colour

  • Topics: Hematology, Oncology

Publish with us